Clinical Trial

Two Bupivacaine Concentrations for Erector Spinae Plane Block in Percutaneous Nephrolithotomy

Study acronym: ESPB-PNL
Completed
View on ClinicalTrials.gov →
Summary
People who undergo percutaneous nephrolithotomy (PNL), a procedure used to remove kidney stones, often experience pain after surgery. An ultrasound-guided erector spinae plane block (ESPB) is commonly used to help reduce this pain. This study compares two different concentrations of bupivacaine, a local anesthetic medication, used during ESPB. Participants undergoing PNL will receive either 0.25% or 0.375% bupivacaine as part of their pain management. Researchers will compare pain scores, the need for additional pain medication, and changes in blood markers related to inflammation after surgery. The aim of the study is to determine whether one concentration provides better pain control or influences the inflammatory response differently after PNL.
Trial Details
NCT Number NCT07653230
Lead Sponsor Ankara Education and Research Hospital
Conditions Percutaneous Nephrolithotomy (PNL), Nephrolithiasis
Enrollment 60 participants
Start Date 2024-07-01
Primary Completion 2025-03-18 (estimated)
Study Completion 2025-03-19 (estimated)
Updated on ClinicalTrials.gov 2026-06-17